Selling, page-134

Again the market is not judicature here on this type of biostock. Your point might be valid with a revenue mining stock or banking. But it holds zero value as an argument for buying or selling these high risk biostocks. All that matters is do the experts in this field see value in spending cash on extra trials. And they do. Their decision are based on science not the share price. Ignore Matt Dune ignor Pro PB. Ignore the Chinese study papers ignore Dan Faber St Jude Alliance, but I will be ignoring shamless down ramping and that is my choice to follow the science.